Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itacitinib for Steroid-Refractory Immune-Related Adverse Events from Immune Checkpoint Inhibitors
NCT05660421Phase 2Withdrawn
- Start
- Mar 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in immune-related adverse events (irAEs). Primary endpoint: Incidence of immune related adverse events (irAE) at 60 days. Planned start Mar 2023; status: withdrawn.
02
Drugs
itacitinib
03
Conditions
immune-related adverse events (irAEs)
Beyond the preview
Go deeper on NCT05660421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660421.